PF 06447475

Discontinued Product

5716 has been discontinued.

View all LRRK2 products.
说明: Potent LRRK2 inhibitor; neuroprotective
化学名: 3-[4-(4-Morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile
纯度: ≥98% (HPLC)
说明书
引用文献 (1)
评论
文献 (1)

生物活性 for PF 06447475

Potent LRRK2 inhibitor (IC50 = 3 nM). Attenuates α-synuclein-induced dopaminergic neurodegeneration and neuroinflammation in G2019S-LRRK2 expressing rats. Also neuroprotective in wild type rats. Brain penetrant.

许可信息

Sold for research purposes under agreement from Pfizer Inc

技术数据 for PF 06447475

分子量 305.33
公式 C17H15N5O
储存 Store at +4°C
纯度 ≥98% (HPLC)
CAS Number 1527473-33-1
PubChem ID 72706840
InChI Key BHTWDJBVZQBRKP-UHFFFAOYSA-N
Smiles N#CC1=CC(C3=CNC2=NC=NC(N4CCOCC4)=C23)=CC=C1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

按产品操作查看相关产品

查看全部 LRRK2 Inhibitors

关键词: PF 06447475, PF 06447475 supplier, PF06447475, potent, LRRK2, inhibitors, inhibits, neurodegeneration, neuroinflammation, brain, penetrant, 5716, Tocris Bioscience

1 篇 PF 06447475 的引用文献

引用文献是使用了 Tocris 产品的出版物。 PF 06447475 的部分引用包括:

Mir et al (2018) The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Biochem J 475 1861 PMID: 29743203


PF 06447475 的评论

目前没有该产品的评论。 Be the first to review PF 06447475 and earn rewards!

Have you used PF 06447475?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.